Interleukin (IL)-18, an important mediator of innate and adaptive immunity, plays multiple roles in chronic inflammation, in autoimmune diseases, in a variety of cancers and in number of infectious diseases. IL-18 promoter polymorphisms have been also noted associated with various inflammatory diseases. We investigated the association of IL-18 promoter polymorphisms (À656T/G, À607A/C and À137C/G) with systemic lupus erythematosus (SLE) in Taiwan Chinese patients and controls. Six haplotypes (hts) were identified from the three promoter polymorphisms. The genotype distribution of the ht1 (GCC), ht2 (TAC), ht4 (GAC) and ht5 (TCC) were different in patients and controls (Po0.002). Moreover, the haplotype and genotype frequencies of ht1 were significantly increased in patients with discoid rash (P ¼ 0.045, odds ratio (OR): 2.01, 95% confidence interval (CI): 1.01-4.00; P ¼ 0.027, OR: 5.13, 95% CI: 1.41-18.68). In addition, the homozygous genotype ht1/ht1 was significant increased in patients with serositis (P ¼ 0.015, OR: 9.78, 95% CI: 1.55-61.73). These observations suggest that the three promoter polymorphisms contribute to the genetic background of SLE pathogenesis.
Introduction
Systemic lupus erythematosus (SLE) is a complex, multifactorial autoimmune disease and characterized by multisystem inflammation and the production of autoantibodies. [1] [2] [3] [4] [5] Arthritis, serum autoantibodies, renal disorder, oral ulcers, skin rash and photosensitivity are developed in combination with one or more symptoms observed in SLE patients. The association of SLE with autoimmunity and inflammation suggests the importance of genes involved in the cytokine network. [6] [7] [8] [9] Moreover, the unbalanced cytokine regulation contributed to the pathogenesis of SLE development has been investigated.
A number of cytokines which associate with the pathogenesis of SLE including interleukin-2 (IL-2), IL-4, IL-6, IL-10, IL-12, IL-17, IL-18, tumor necrosis factor-a (TNF-a) and interferon-g (IFN-g) have been reported. [10] [11] [12] [13] [14] [15] Among these cytokines, elevated serum IL-18 of SLE patients are observed as compared with normal individuals. [11] [12] [13] 16 IL-18, a member of the IL-1 cytokine family, is a proinflammatory cytokine. This cytokine is now recognized as an important regulator of innate and acquired immune responses and plays multiple roles in chronic inflammation, in autoimmune diseases, in a variety of cancers and in number of infectious diseases. [17] [18] [19] The IL-18 in combination with other proinflammatory cytokines like TNF, IL-6 or IFN-g may play a major role in propagating the inflammatory processes responsible for tissue destruction. 15 The regulation of IL-18 expression is regulated by the IL-18 promoter gene. [20] [21] [22] In addition, the IL-18 promoter polymorphisms at position À607 and À137 in the promoter 1 region are found to be associated with the IL-18 gene promoter transcription activity. 23, 24 The low promoter activity was observed for A and C alleles at position À607 and À137, respectively. In contrast, higher promoter activity was observed for C and G alleles in those positions. These polymorphisms in IL-18 have been noted associated with various inflammatory diseases such as allergic rhinitis, asthma and rheumatoid arthritis. [25] [26] [27] [28] The IL-18 promoter and IL-18 gene represent attractive candidate regions for gene polymorphism analyses in SLE. In this study, the À656, À607 and À137 positions in the promoter region of IL-18 polymorphisms in SLE patients from Taiwan Chinese population have been examined in association with disease susceptibility.
Results
Allele and genotype frequencies of IL-18 promoter polymorphisms A total of 172 patients with SLE meeting the American Rheumatism Association criteria, and 160 healthy subjects comprise the Taiwan Chinese cohort. The genotypes of the three promoter polymorphisms including À656T/ G, À607A/C and À137C/G were identified by the probe hybridization method in Taiwan Han Chinese SLE patients and controls with corresponding primers and probes (Table 1) . 29, 30 However, the total numbers for SLE patients or controls illustrated in Table 1 do not agree with each other for the three polymorphisms may be due to the bad quality of the genomic DNA of SLE patients or controls. The bad quality of the genomic DNA may lead to polymerase chain reaction (PCR) failure. Therefore, the total numbers for SLE patients or controls mean the success in PCR reaction numbers. The allele and genotype frequencies of the three promoter polymorphisms are shown in Table 2 (also see Supplementary data 5). The three genotype distributions were in HardyWeinberg equilibrium. The allele and genotype frequencies of these polymorphisms were not statistically different in the patients and controls ( Table 2) .
Frequencies of IL-18 promoter haplotype Haplotype frequencies were estimated using the three promoter polymorphisms with an allele frequency 45% (Table 3 and Supplementary data 4). Of the eight observed haplotypes, six were present both in SLE patients and in controls. The frequency of most common haplotype (Ht1-GCC) in controls was 45% as compared with 24.8% in the SLE patients ( IL-18 promoter polymorphisms and clinical features of SLE As for haplotype association study with clinical features, there was no significance in any other haplotypes except ht1 (data not shown). The association between the clinical features profile of SLE patients with various alleles and genotypes was analyzed and the result was shown in Table 4 . The haplotype frequency of ht1 was significantly increased in patients with discoid rash (P ¼ 0.045, OR: 2.01, 95% CI: 1.01-4.00) (also see Supplementary data 3 and 9). The IL-18 promoter genotype frequency was also significantly different in patients in the presence of discoid rash. The heterozygous genotype ht1/non-ht1 associated with discoid rash (P ¼ 0.027, OR: 5.13, 95% CI: 1.41-18.68). The allele and genotype frequencies of ht1 were significantly increased in patients with discoid rash. In addition, the IL-18 promoter genotype frequency was also significantly different in patients in the presence of serositis. The homozygous genotype ht1/ht1 associated with serositis (P ¼ 0.015, OR: 9.78, 95% CI: 1.55-61.73).
Discussion
Many studies have examined the relationship between cytokine gene polymorphisms and the incidence of SLE, including IL-4, IL-6, IL-10, TNF-a and IFN-g receptor. 3, [31] [32] [33] [34] [35] [36] [37] In this study, this is the first investigation of the association of IL-18 promoter polymorphisms with 16, 38 In addition, SLE patients have significant higher serum concentrations of IL-18. 16 From the SLE development, the deficiency in enhanced gene transcription will be beneficial for the individual, as elevated levels of the proinflammatory IL-18 protein mediate many of the acute and chronic inflammatory processes. Indeed, studies in anticytokine therapy including TNF, IL-6, IL-18 and IFN-g in SLE have become an important issue in preventing from tissue damage. 15, 39 Several studies showed functional data that related IL-18 production level to IL-18 promoter gene. [20] [21] [22] [23] [24] Nine single-nucleotide polymorphisms (SNPs) in the IL-18 gene have been identified, including À656, À607, À137 of promoter 1, À920, À133, À132 of promoter 2 and 105, 113, 127 of exon 1 (also see Supplementary data 7 and 8). Among these polymorphisms, only two promoter polymorphisms of À607 and À137 of IL-18 promoter 1 region are suggested that can cause differences in transcription factor binding by comparison of the IL-18 gene promoter fragment. Furthermore, a change from C to A at position À607 disrupts a potential cAMP-responsive element binding protein (CREB) site resulting in low IL-18 production. 40 Similarly, a change at position À137 from G to C affects the H4TF-1 nuclear factor binding site. 23, 41 In conclusion, from the IL-18 gene promoter transcription activity studies suggest that higher frequencies of A and C alleles at positions À607 and À137, respectively, would lead to low promoter activity. Alternatively, higher frequencies of C and G alleles at positions À607 and À137, respectively, would confer higher promoter activity.
IL-18 promoter polymorphisms have been associated with many immune-mediated inflammatory diseases including allergic rhinitis, asthma and rheumatoid arthritis (RA). [25] [26] [27] [28] Thus, these polymorphisms could not be specific for SLE. The IL-18 promoter polymorphism data of various case-control studies are also not absolutely conclusive. A Polish population showed an important contribution of À137C and À137CC to the genetic risk in type I diabetes and a protective effect of À607AA. 42 In a Chinese population, the AA genotype at position À607, but not at À137, is associated with a protective effect against development of RA. 43 However, in Caucasian RA patients, the conclusion is not the same in Chinese RA patients. 44 The À607C-137C haplotype was more prevalent in German RA and in Scottish RA patients than in the controls. In both German and Scottish population, both SNPs at position À607 and À137 contribute to the genetic background of RA pathogenesis.
In our study, we observed that the ht1 (GCC) haplotype was less in SLE patients (24.8%) than in controls (45%). The ht2 (TAC) haplotype was also less in SLE patients (22.2%) than in controls (41.8%). The ht1 and ht2 haplotypes seem to play a protective effect in preventing SLE development. On the contrary, the ht4 (GAC) haplotype was more prevalent in SLE patients (22.5%) than in controls (1.1%). The ht5 (TCC) haplotype was more prevalent in SLE patients (16.2%) than in controls (0.8%). The ht4 and ht5 haplotypes seem to play a susceptibility factor in developing SLE. A previous report showed that haplotype-TAC at position À656, À607 and À137, respectively, would lead to low promoter activity compared with other haplotypes-GCG and TAG.23 This may answer why the ht2 (TAC) haplotype is less in SLE patients than in controls because elevated serum IL-18 of SLE patients are observed as compared with normal individuals. [11] [12] [13] 16 However, no further information about ht4 (GAC) haplotype in promoter activity assay is available. We cannot exclude other polymorphism-like position at À656 which may also contribute to the transcriptional activity of IL-18. Further IL-18 promoter activity studies in characterizing haplotype effect remain to be characterized. Besides the transcriptional regulation, post-translational modifications also may appear relevant for the control of IL-18 bioactivity.
For clinical features analysis, we found that the haplotype and genotype frequencies of ht1 were significantly increased in patients with discoid rash. The homozygous genotype ht1/ht1 was significantly increased in patients with serositis. If the high frequency of ht1 haplotype is associated with low IL-18 production, it could be concluded that low IL-18 production may be the risk factor in discoid rush and serositis with SLE, despite low IL-18 production being a protective factor in developing SLE.
In conclusion, the present findings illustrated the À656, À607 and À137 positions in the promoter region of IL-18 polymorphisms in SLE patients from Taiwan Chinese population in association with disease susceptibility. These observations suggest that the three promoter polymorphisms contribute to the genetic background of SLE pathogenesis.
Patients and methods

Patients
The study subjects including a total of 172 patients with SLE and 160 healthy subjects were recruited from China Medical University Hospital in Taiwan (see Supplementary data 1 and 2). The SLE patients all met the American Rheumatism Association criteria for the classification of SLE. 45 This study was performed on SLE patients available during the period of collecting samples, diagnosed with inactive or active disease, untreated or treated with steroids. The healthy control from the general population was selected from health examination. All individuals' samples were collected by venipuncture for genomic DNA isolation. Informed consent was obtained from SLE patients and healthy control participating in this study and was approved by the local Ethics Committee.
Genomic DNA extraction and genotyping The genomic DNA was extracted from peripheral blood leukocytes according to standard protocols (Genomic DNA kit; Qiagen, Valencia, CA, USA). The three IL-18 promoter polymorphisms were detected by employing the LightCycler 480 Instrument (Roche Diagnostics, Indianapolis, IN, USA). 29, 30 Briefly, PCR was performed in the presence of 0.5 mM sense primer, 1 mM antisense primer, 2 nM MgCl 2 , 2 ml of Â 10 Lightcycler DNA master hybridization probes (Roche Diagnostics, Indianapolis, IN, USA) and 0.2 mM of each fluorescence probe (Table 1) .
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After initial denaturation for 10 min at 951C, 55 cycles were run, each consisting of denaturation (951C for 0 s), annealing (571C for 10 s) and extension (721C for 20 s). The melting curve analysis was performed as follows: one cycle, 951C for 0 s, 451C for 60 s followed by the gradual increase of 0.11C/s to the target temperature of 801C.
Statistical analysis
The genotype frequency and allelic frequency distributions in the polymorphisms in both SLE patients and controls were analyzed by the w 2 method. SPSS Version 10.0 software was used to analyze the data. A P-value o0.05 was considered statistically significant. Allelic frequencies were expressed as a percentage of the total number of alleles. OR were calculated from genotype frequencies and allelic frequencies with 95% CI. Haplotypes were inferred from unphased genotype data using the Bayesian statistical method available in the program Phase 2.1. 46, 47 Adherence to the Hardy-Weinberg equilibrium constant was tested using a w 2 test with a one degree of freedom (see Supplementary data 6).
